Phase 1 study of novel anti-platelet agent to overcome pharmacogenomic limitations of clopidogrel
Aims Clopidogrel is the most commonly prescribed thienopyridine as part of dual anti-platelet therapy for the treatment of cardiovascular diseases. However, clopidogrel responsiveness shows variability based on CYP2C19 polymorphism. Therefore, we planned a study with an objective of evaluating safet...
Saved in:
Main Authors: | Anil Pareek, Nitin Chandurkar, Vivek Raut, Kumar Naidu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2025-02-01
|
Series: | Open Heart |
Online Access: | https://openheart.bmj.com/content/12/1/e003088.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Migratory Polyarthritis Associated With Clopidogrel: A Case Report
by: Hamid Khederlou, et al.
Published: (2024-12-01) -
Systematic analysis of the pharmacogenomics landscape towards clinical implementation of precision therapeutics in Greece
by: George P. Patrinos, et al.
Published: (2025-02-01) -
Stigma and mental health: overcoming barriers
by: Mythily Subramaniam
Published: (2024-10-01) -
Overcoming single-technology limitations in digital heritage preservation: A study of the LiPhoScan 3D reconstruction model
by: Yao Wang, et al.
Published: (2025-04-01) -
Overcoming hypoxia-induced breast cancer drug resistance: a novel strategy using hollow gold-platinum bimetallic nanoshells
by: Lian-Ying Zhang, et al.
Published: (2025-02-01)